SLU-PP-332: What Researchers Need to Know in 2026

SLU-PP-332 has quietly become one of the most discussed compounds in the exercise mimetic research space. Developed at Saint Louis University, this small molecule targets a nuclear receptor that governs mitochondrial biogenesis, fat oxidation, and endurance capacity — activating the molecular machinery behind aerobic fitness through pharmacological means rather than physical training. For researchers studying metabolic disease, obesity, and performance physiology, it represents a genuinely novel mechanism worth understanding.

What Is SLU-PP-332?

SLU-PP-332 is a synthetic agonist of ERRα — estrogen-related receptor alpha — a nuclear receptor that acts as a master regulator of mitochondrial function and oxidative metabolism. ERRα is an orphan receptor, meaning it has no known natural ligand. Researchers at St. Louis University developed SLU-PP-332 specifically to activate this receptor pharmacologically, hence the compound’s name.

When ERRα is activated, it triggers a cascade of gene expression changes that closely mirror what happens inside muscle cells during sustained aerobic exercise. Mitochondria multiply. Muscle fiber types shift from glycolytic (fast-twitch, Type II) to oxidative (slow-twitch, Type I). Fat oxidation pathways open up. The compound signals cells to prepare for prolonged endurance output — even in the absence of physical activity. This is why SLU-PP-332 is often classified as an “exercise mimetic.”

Research Overview

The landmark preclinical study on SLU-PP-332 was conducted at the University of Florida’s Burris Lab and published in Nature Communications (2023). Treated mouse models demonstrated statistically significant improvements in run-to-exhaustion treadmill testing, increased mitochondrial density in skeletal muscle tissue, and broad metabolic improvements. ERRα was confirmed as the mechanism of action through genetic knockout controls — animals lacking ERRα did not show the same benefits.

The scientific interest in this receptor predates SLU-PP-332. A foundational body of ERRα literature spans over a decade:

• ERRα and exercise mimicry — PubMed literature review
• SLU-PP-332 compound research — Google Scholar
• Community discussion: r/Peptides SLU-PP-332 thread

It is critical to note that all published data on SLU-PP-332 involves animal models. No human clinical trials have been registered or completed as of 2026. The mechanistic foundation is compelling, but human translational data does not yet exist.

Potential Benefits Studied

Based on preclinical research, investigators have examined the following areas of interest:

• Enhanced endurance capacity — treated mice showed dramatically improved run-to-exhaustion metrics in treadmill testing, with some studies reporting endurance increases exceeding 50% compared to controls
• Mitochondrial biogenesis — increased mitochondrial density in skeletal muscle tissue, suggesting improved cellular energy production capacity
• Muscle fiber type switching — documented shift from fast-twitch (Type II) to slow-twitch (Type I) fiber composition, associated with improved oxidative capacity
• Increased fat oxidation — activation of fat-burning gene programs relevant to body composition and metabolic health research
• Metabolic disease applications — researchers have proposed SLU-PP-332 as a candidate for studying obesity, type 2 diabetes, sarcopenia, and conditions where exercise capacity is functionally impaired
• Cardioprotective signaling — ERRα is expressed in cardiac tissue; preliminary data suggests the compound may activate cardiac metabolic adaptations similar to those induced by aerobic conditioning

Dosage & Administration

No established human dosing protocols exist for SLU-PP-332. Preclinical research used intraperitoneal administration in mouse models at doses that do not translate linearly to human equivalents. Researchers working with this compound for in vitro or animal research applications should reference the original published literature for species-appropriate dosing parameters.

The 500mcg format available at Combat Research is supplied for research purposes only and is not intended for human consumption. All research applications should comply with applicable institutional and regulatory guidelines.

Where to Find It

SLU-PP-332 500mcg is available for research purposes at combatresearch.is. Combat Research provides research-grade compounds for legitimate scientific investigation.

Conclusion

SLU-PP-332 is one of the most mechanistically compelling compounds in current exercise science research. Its ability to pharmacologically activate ERRα — and thereby initiate a coordinated transcriptional program that mimics endurance training adaptation — makes it a powerful investigative tool for studying metabolic physiology, muscle biology, and the molecular basis of fitness. The preclinical evidence is strong and reproducible. The translational gap remains. For researchers operating at the intersection of pharmacology and exercise science, SLU-PP-332 is a compound that warrants serious, sustained attention.

Disclaimer

This article is for educational and research purposes only. SLU-PP-332 has not been approved by the FDA for human use. All data referenced reflects preclinical animal-model research. This is not medical advice. Consult a licensed healthcare professional before making any health-related decisions.